ABSI Absci Corp Insider Trading

Director Mary T Szela purchased 12,900 shares of ABSI at $11.54; holdings increased 153.6% to 21,300 shares

Director Mary T Szela purchased 12,900 shares of Absci Corp at $11.54 on 2026-06-30, tripling her position from 8,400 to 21,300 shares and representing a 153.6% increase in holdings. The purchase occurs within the 52-week range at $11.54 (4.3% below the 52-week high of $12.06) and follows a sharp 30-day rally of +80.3% and 90-day surge of +295.2%. However, this buy follows a weak cross-ticker track record for this insider: her prior 10 purchases across all tickers averaged 90-day returns of -8.0% with a 33.33% win rate, suggesting this trade pattern has historically underperformed. Against this backdrop, ABSI remains unprofitable with a full-year net income of $-29.6M, annual revenue contracted -38.2%, and latest quarterly revenue of only $215.0K—a significant mismatch between the large accumulation and fundamental deterioration that requires scrutiny of the transaction's motivation.

Director Pangalos purchases 37,453 shares at market; third open-market buy in 36 months with perfect prior timing history.

Director Menelas Pangalos is making his third open-market purchase of Absci shares in the past three years, adding nearly 20% to his existing stake. The timing is notable: the stock is trading well below its 52-week high and has experienced sharp volatility, but this purchase comes after strong recent momentum over the preceding months. Pangalos has a flawless track record with his two prior purchases at this company—both trades were followed by significant gains at the 90-day mark, suggesting strong timing judgment on this stock specifically. He is doubling down on a company that is unprofitable and facing declining revenue, but the director's consistent willingness to deploy capital at lower prices, coupled with his historical success on this ticker, indicates conviction despite the current fundamentals. This is not a casual trade: it represents meaningful capital allocation and a pattern of accumulation by someone with board-level insight into the company's trajectory.

Chief Innovation Officer Andreas Busch bought 100,000 ABSI shares at $2.29; holdings now 421,446 (+31.1%). Stock down -50.0% from 52-week high.

Andreas Busch, Chief Innovation Officer, purchased 100,000 shares at $2.29, increasing his holdings by 31.1% to 421,446 shares. The timing is notable: his prior purchase at ABSI in July 2025 achieved a 90-day return of +40.5%, and his cross-ticker track record shows a 100% win rate on buys at the 90-day mark, averaging +40.5% over that horizon. However, current context is materially weaker—the stock trades at $2.50, down -50.0% from the $5.00 52-week high and -29.6% over the past 90 days. The company is unprofitable (net income $-28.7M in the latest quarter) with declining revenue (-20.7% year-over-year). The purchase occurs in a depressed price environment relative to recent history, but against deteriorating operational fundamentals.

Director Pangalos Menelas N purchased 75,095 shares of ABSI at $2.74; holdings surge 65.9% to 189.1K shares despite stock down 48.6% from 52-week high.

Pangalos Menelas N acquired 75,095 shares at $2.74 on 2026-02-27, expanding his stake by 65.9% to 189.1K shares. This is the director's second open-market purchase at Absci Corp; his prior September 2025 buy at this ticker returned +61.1% over 30 days and +27.1% over 90 days, marking a well-timed entry. However, the current acquisition arrives in a challenging context: ABSI trades at $2.57, down 48.6% from its 52-week high of $5.00, and the company faces fundamental headwinds with negative net income of $-28.7M last fiscal year and annual revenue contraction of -20.7%. The timing and scale of this purchase—combined with his successful prior entry point—merit scrutiny, yet the stock's severe recent decline and unprofitable operations mean any conviction signal must be weighed against deteriorating business fundamentals.

Director VAN HOUTEN FRANS bought 40,000 shares of ABSI at $3.72; holdings tripled to 63,320 shares amid -20.7% revenue decline and $-28.7M net loss.

VAN HOUTEN FRANS, a Director, purchased 40,000 shares at $3.72, increasing his holdings by 171.5% to 63,320 shares and deploying $148,800.00 in the transaction. This material accumulation occurs against a backdrop of deteriorating fundamentals: Absci reported latest-quarter revenue of $378,000.00 and a full-year net income of $-28.7M, with annual revenue declining 20.7% year-over-year. The stock is currently trading at $3.52, down 39.5% from its 52-week high of $5.82, though it has recovered 47.9% over the prior 90 days and 5.6% in the last 30 days. The purchase price of $3.72 sits between the current price and the 52-week low of $2.24, suggesting the acquisition occurred as the stock was rebounding from depressed levels. An investor should note that insider accumulation in a deeply unprofitable company with shrinking revenues typically signals conviction about turnaround prospects, but the fundamental trajectory warrants careful scrutiny of management's path to profitability and any material operational changes announced since this filing date.

Director Pangalos purchased 95,785 shares at $2.66; holdings now 113,960 shares (+527.0% vs prior), amid -20.7% revenue decline and $-30.6M annual net loss.

Director Pangalos Menelas N acquired 95,785 shares for $254,788.10, increasing his position by 527.0% to 113,960 shares total. This substantial absolute purchase occurs in a company generating only $593,000 in latest-quarter revenue while reporting a full-year net loss of $-30.6M and experiencing -20.7% annual revenue decline. The stock has declined -57.2% from its 52-week high of $5.82 to the current $2.49 price. The magnitude of this position increase and the timing relative to severely deteriorated fundamentals warrant examination of whether this reflects insider confidence in operational turnaround prospects or other material considerations not yet disclosed in public filings.

SVP, CAO Bedrick Todd bought 10,000 shares of ABSI at $2.70 on 2025-09-22; stock down -57.2% from 52-week high.

Bedrick Todd, serving as SVP and CAO, purchased 10,000 shares at $2.70, increasing his holdings by 5.9% to 180,428 shares. The transaction occurred at a significant discount to the 52-week high of $5.82, with the stock currently trading 2.0% lower over the past 30 days. Absci remains unprofitable with a net income of $-30.6M in the most recent period, and the company has experienced annual revenue decline of -20.7% year-over-year, indicating substantial operational headwinds that merit scrutiny of insider motivations.

Chief Innovation Officer Busch Andreas buys 50,000 shares at $3.04 amid -20.7% annual revenue decline and -26.3M net loss.

Busch Andreas, Chief Innovation Officer, purchased 50,000 shares at $3.04 on 2025-07-28, increasing his holdings by 18.0% to 327,264 shares post-transaction. The purchase occurs while Absci Corp faces significant operational headwinds: annual revenue declined 20.7% year-over-year, the company posted a full-year net loss of -26.3M, and the current stock price of $2.95 is -49.3% from the 52-week high of $5.82. Despite the transaction occurring at $3.04, which is above the current market price, the broader context reveals a company in financial distress. An insider investment during such deterioration warrants attention to whether this reflects confidence in a turnaround strategy aligned with his innovation leadership role, or whether it represents an isolated personal allocation decision disconnected from the company's trajectory.